Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.78) by 2.56 percent. This is unchanged from the same period last year.
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Glaukos Corp (NYSE:GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System.…